Seeking Alpha

SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)

JERSEY CITY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (SCYX) (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and ...

Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort

Interim data from Phase 1 with single and multiple ascending doses show no safety signals and a generally favorable tolerability profile of ...
USA Today

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage

Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 MIAMI, FL / ACCESS Newswire / August 19, 2025 / MIRA Pharmaceuticals, Inc.
Nasdaq

Voyager Therapeutics Reports Positive Data From Single Ascending Dose Study Of VY7523

(RTTNews) - Voyager Therapeutics, Inc. (VYGR) Monday announced positive topline data from its single ascending dose (SAD) study of VY7523 developed for the treatment of Alzheimers disease (AD). The ...